YU47100A - Novi derivati dihidroksiheksanoinske kiseline - Google Patents

Novi derivati dihidroksiheksanoinske kiseline

Info

Publication number
YU47100A
YU47100A YU47100A YU47100A YU47100A YU 47100 A YU47100 A YU 47100A YU 47100 A YU47100 A YU 47100A YU 47100 A YU47100 A YU 47100A YU 47100 A YU47100 A YU 47100A
Authority
YU
Yugoslavia
Prior art keywords
acid derivatives
dihydroxahexanoic
novel
useful
general formula
Prior art date
Application number
YU47100A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
John Charles Kath
Matthew Frank Brown
Christopher Stanley Poss
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU47100A publication Critical patent/YU47100A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
YU47100A 1998-02-05 1999-01-18 Novi derivati dihidroksiheksanoinske kiseline YU47100A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05

Publications (1)

Publication Number Publication Date
YU47100A true YU47100A (sh) 2002-11-15

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
YU47100A YU47100A (sh) 1998-02-05 1999-01-18 Novi derivati dihidroksiheksanoinske kiseline

Country Status (36)

Country Link
EP (1) EP1051405B1 (OSRAM)
JP (1) JP3693916B2 (OSRAM)
KR (1) KR100385529B1 (OSRAM)
CN (1) CN1177834C (OSRAM)
AP (1) AP992A (OSRAM)
AR (1) AR016175A1 (OSRAM)
AT (1) ATE337307T1 (OSRAM)
AU (1) AU752407B2 (OSRAM)
BG (1) BG104726A (OSRAM)
BR (1) BR9907655A (OSRAM)
CA (1) CA2320388C (OSRAM)
DE (1) DE69932920T2 (OSRAM)
DZ (1) DZ2717A1 (OSRAM)
EA (1) EA003137B1 (OSRAM)
ES (1) ES2268847T3 (OSRAM)
GT (1) GT199900011A (OSRAM)
HR (1) HRP20000529B1 (OSRAM)
HU (1) HUP0100832A3 (OSRAM)
IL (1) IL137330A0 (OSRAM)
IS (1) IS5562A (OSRAM)
MA (1) MA26603A1 (OSRAM)
MY (1) MY133125A (OSRAM)
NO (1) NO20003965D0 (OSRAM)
NZ (1) NZ505724A (OSRAM)
OA (1) OA11448A (OSRAM)
PA (1) PA8467301A1 (OSRAM)
PE (1) PE20000243A1 (OSRAM)
PL (1) PL342817A1 (OSRAM)
SK (1) SK11262000A3 (OSRAM)
TN (1) TNSN99013A1 (OSRAM)
TR (1) TR200002248T2 (OSRAM)
TW (1) TW470744B (OSRAM)
UA (1) UA57824C2 (OSRAM)
WO (1) WO1999040061A2 (OSRAM)
YU (1) YU47100A (OSRAM)
ZA (1) ZA99873B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1152752A1 (en) * 1999-01-29 2001-11-14 Millennium Pharmaceuticals, Inc. Methods for preventing graft rejection and ischemia-reperfusion injury
CA2376275A1 (en) * 1999-08-20 2001-03-01 Michael John Ricks Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
CA2399214A1 (en) * 2000-02-04 2001-08-09 Matthew Frank Brown Novel heterocyclic amide derivatives
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE60238193D1 (de) 2001-06-22 2010-12-16 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
JP2005527604A (ja) * 2002-05-14 2005-09-15 ファイザー・プロダクツ・インク ジヒドロフラン2オン誘導体の製造方法
WO2003095440A1 (en) 2002-05-14 2003-11-20 Pfizer Products Inc. Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making
PL375345A1 (en) 2002-08-12 2005-11-28 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
JP2005538130A (ja) * 2002-08-12 2005-12-15 ファイザー・プロダクツ・インク キノキサリン−2−カルボン酸[4−カルバモイル−1−(3−フルオロベンジル)−2,7−ジヒドロキシ−7−メチル−オクチル]−アミドの結晶形
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
EP1653927B1 (en) 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
ATE220661T1 (de) * 1994-10-19 2002-08-15 Novartis Erfind Verwalt Gmbh Antivirale ether von aspartat-protease-substrat- isosteren
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
ZA99873B (en) 2000-08-04
WO1999040061A2 (en) 1999-08-12
EP1051405A2 (en) 2000-11-15
MY133125A (en) 2007-10-31
ES2268847T3 (es) 2007-03-16
IS5562A (is) 2000-07-14
TNSN99013A1 (fr) 2005-11-10
PE20000243A1 (es) 2000-04-07
CA2320388A1 (en) 1999-08-12
EP1051405B1 (en) 2006-08-23
OA11448A (en) 2003-11-18
SK11262000A3 (sk) 2001-01-18
AU752407B2 (en) 2002-09-19
AP9901457A0 (en) 1999-03-31
HRP20000529A2 (en) 2001-08-31
HK1034969A1 (en) 2001-11-09
HRP20000529B1 (en) 2004-12-31
ATE337307T1 (de) 2006-09-15
NO20003965L (OSRAM) 2000-10-03
DE69932920D1 (de) 2006-10-05
CA2320388C (en) 2005-05-03
WO1999040061A3 (en) 1999-10-21
EA003137B1 (ru) 2003-02-27
DE69932920T2 (de) 2007-02-08
NO20003965D0 (no) 2000-08-04
AR016175A1 (es) 2001-06-20
KR20010040684A (ko) 2001-05-15
BR9907655A (pt) 2000-10-24
IL137330A0 (en) 2001-07-24
AU1778999A (en) 1999-08-23
TW470744B (en) 2002-01-01
JP3693916B2 (ja) 2005-09-14
GT199900011A (es) 2000-07-20
MA26603A1 (fr) 2004-12-20
JP2002502839A (ja) 2002-01-29
PL342817A1 (en) 2001-07-02
UA57824C2 (uk) 2003-07-15
CN1177834C (zh) 2004-12-01
EA200000741A1 (ru) 2001-02-26
KR100385529B1 (ko) 2003-05-27
CN1290255A (zh) 2001-04-04
BG104726A (en) 2001-04-30
TR200002248T2 (tr) 2000-12-21
HUP0100832A3 (en) 2002-03-28
AP992A (en) 2001-08-06
NZ505724A (en) 2003-02-28
PA8467301A1 (es) 2000-05-24
DZ2717A1 (fr) 2003-09-01
HUP0100832A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
MY121294A (en) Novel hexanoic acid derivatives.
YU47100A (sh) Novi derivati dihidroksiheksanoinske kiseline
IL112495A0 (en) Phenylacetic acid derivatives, their preparation and compositions containing them
IL129068A0 (en) Sulfinic acid derivatives and their preparation and use
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
PT1190713E (pt) Inibicao dos intermediarios de produtos finais de glicosilacao avancada e pos-amadori.
MX9600487A (es) Composiciones topicamente administrables que contienen derivados de acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
IL147184A0 (en) Substituted benzimidazole
TR199900308T2 (xx) Tiyenopirimidinler
BG106406A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO1993000330A3 (en) Azanorbornane derivatives
IL149272A0 (en) Substituted indoles for modulating nfkb activity
HUP0004592A2 (hu) VCAM-1 expresszió gátlására alkalmas vegyületek és eljárások
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
IL104716A0 (en) Aminoacetylmercapto derivatives useful as inhibitors of enkephalinase and ace
MY109722A (en) Azaoxindole derivatives.
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
IL150125A0 (en) Novel compounds
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
DE69525740D1 (de) Spezielle halofantrinhaltige Zusammensetzungen
MY128261A (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
IL106748A0 (en) 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
BG100248A (bg) Инхибитори на скваленсинтетаза